New England Research & Management Inc. boosted its stake in shares of HCA Healthcare Inc (NYSE:HCA) by 50.7% during the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 5,200 shares of the company’s stock after buying an additional 1,750 shares during the period. New England Research & Management Inc.’s holdings in HCA Healthcare were worth $678,000 as of its most recent filing with the SEC.
A number of other hedge funds also recently made changes to their positions in HCA. Oregon Public Employees Retirement Fund grew its stake in shares of HCA Healthcare by 16,494.3% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 11,119,359 shares of the company’s stock worth $89,000 after acquiring an additional 11,052,352 shares in the last quarter. Norges Bank bought a new position in HCA Healthcare during the fourth quarter worth $359,391,000. AQR Capital Management LLC boosted its position in HCA Healthcare by 433.7% during the third quarter. AQR Capital Management LLC now owns 1,293,241 shares of the company’s stock worth $179,916,000 after purchasing an additional 1,050,940 shares during the period. Canada Pension Plan Investment Board boosted its position in HCA Healthcare by 111.5% during the fourth quarter. Canada Pension Plan Investment Board now owns 1,614,102 shares of the company’s stock worth $200,858,000 after purchasing an additional 850,902 shares during the period. Finally, Point72 Asset Management L.P. boosted its position in HCA Healthcare by 547.2% during the third quarter. Point72 Asset Management L.P. now owns 873,660 shares of the company’s stock worth $121,544,000 after purchasing an additional 738,660 shares during the period. Hedge funds and other institutional investors own 71.49% of the company’s stock.
NYSE:HCA opened at $124.56 on Friday. HCA Healthcare Inc has a 1-year low of $93.03 and a 1-year high of $147.42. The stock has a market cap of $42.54 billion, a PE ratio of 12.75, a PEG ratio of 1.00 and a beta of 0.78.
The firm also recently declared a quarterly dividend, which was paid on Friday, March 29th. Shareholders of record on Friday, March 1st were paid a $0.40 dividend. The ex-dividend date of this dividend was Thursday, February 28th. This is a positive change from HCA Healthcare’s previous quarterly dividend of $0.35. This represents a $1.60 annualized dividend and a yield of 1.28%. HCA Healthcare’s payout ratio is 16.38%.
In other HCA Healthcare news, SVP Deborah M. Reiner sold 466 shares of the business’s stock in a transaction that occurred on Tuesday, February 5th. The stock was sold at an average price of $139.07, for a total value of $64,806.62. Following the transaction, the senior vice president now directly owns 5,037 shares of the company’s stock, valued at $700,495.59. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Deborah M. Reiner sold 523 shares of the business’s stock in a transaction that occurred on Thursday, January 31st. The shares were sold at an average price of $138.89, for a total value of $72,639.47. Following the completion of the transaction, the senior vice president now directly owns 4,927 shares in the company, valued at $684,311.03. The disclosure for this sale can be found here. Over the last three months, insiders sold 78,476 shares of company stock worth $10,940,008. Insiders own 2.70% of the company’s stock.
A number of equities analysts have commented on HCA shares. Barclays reduced their price objective on shares of HCA Healthcare from $155.00 to $145.00 and set an “overweight” rating for the company in a research report on Wednesday, April 17th. Deutsche Bank initiated coverage on HCA Healthcare in a report on Thursday, January 3rd. They set a “buy” rating and a $140.00 target price for the company. Raymond James raised HCA Healthcare from a “market perform” rating to an “outperform” rating and lifted their target price for the stock from $115.00 to $135.00 in a report on Tuesday. Oppenheimer lifted their target price on HCA Healthcare from $142.00 to $150.00 and gave the stock an “outperform” rating in a report on Wednesday, January 30th. Finally, ValuEngine downgraded HCA Healthcare from a “buy” rating to a “hold” rating in a research note on Wednesday, March 6th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and eighteen have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $147.59.
About HCA Healthcare
HCA Healthcare, Inc, through its subsidiaries, provides health care services. The company operates general, acute care hospitals that offer medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy services.
Featured Story: What is Cost of Capital?
Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.